Chapter 35: Impact of Inhaled Insulin on the Insulin Market

Impact of inhaled insulin on the insulin market There is considerable need for an insulin delivery system that will eliminate the requirement for multiple daily injections in type 1 and type 2 diabetes patients. Recognition of this need has prompted several companies to begin developing less-invasive methods of insulin administration. The first of these alternative methods is an inhaled formulation of rapid-acting insulin, Pfizer's Exubera, launched in the US market in September 2006. The advent of this technology has the potential to impact the insulin market significantly by adding new players and may change medical practice as barriers to the initiation of insulin therapy are lowered. This chapter provides an overview of current insulin therapy, including various delivery devices, and a review of insulin use in the treatment of diabetes. We provide detailed information on Exubera, the first inhaled-insulin product to come to market. Several other inhaled-insulins are in late-stage ...

Users without subscription are not able to see the full content on this title. Please, subscribe or login to access all content on this website.

• Buy The Book